Peptide Schedule
Bonomarlot6 residuesAEDRVGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bonomarlot
Benefits
About Bonomarlot
Bonomarlot is a peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson's research program. It's derived from bovine bone marrow tissue and contains short-chain peptides typically 2-7 amino acids in length. The product is classified as part of the Cytomax line of tissue-specific bioregulators and carries the designation A-20. Bone marrow serves as the primary site of hematopoiesis — the production of red blood cells, white blood cells, and platelets from hematopoietic stem cells. It's also home to mesenchymal stem cells that can differentiate into bone, cartilage, and fat tissue. Age-related decline in bone marrow function contributes to immunosenescence, anemia, and reduced regenerative capacity. Bonomarlot's proposed function is to restore normal gene expression patterns in bone marrow tissue by delivering tissue-specific peptide fragments. Khavinson's broader research program has shown that short peptides can enter cell nuclei, interact with histone proteins and DNA promoter regions, and influence transcription. Related peptides like AED, KED, and KE have been studied in human bone marrow mesenchymal stem cells, where they modulated expression of senescence-related genes including IGF1, FOXO1, and TERT. No peer-reviewed clinical trials specific to Bonomarlot have been published. The product's theoretical basis rests on Khavinson's general bioregulator research and separate myelopeptide studies by Petrov and colleagues, which identified immunoregulatory hexapeptides produced by bone marrow cells.
Who Should Consider Bonomarlot
- Adults over 50 experiencing age-related immune decline or reduced blood cell counts
- Individuals interested in Khavinson bioregulator protocols for immune support
- Those seeking oral peptide alternatives to injectable immune-modulating peptides
- Researchers studying peptide-mediated gene expression in bone marrow stem cells
- People with documented hematopoietic decline under medical supervision
How Bonomarlot Works
Bonomarlot's proposed mechanism follows the general Khavinson bioregulator model. The short peptides (di- to heptapeptides) in the formulation are thought to survive gastric digestion due to their small size and can be absorbed through intestinal epithelium via peptide transporters like PepT1 (SLC15A1) and LAT carriers. Once absorbed, these tissue-specific peptides are proposed to enter bone marrow cells and penetrate the nucleus, where they interact with nucleosomes and histone proteins at specific DNA sequences. Research on related Khavinson peptides (AED, KED, KE) in human bone marrow mesenchymal stem cells has demonstrated modulation of IGF1 expression (3.5-5.6 fold increase), FOXO1 regulation, and TERT gene activity — all linked to cellular senescence pathways. The broader myelopeptide research by Petrov and Mikhailova identified that bone marrow naturally produces regulatory hexapeptides (MP-1 and MP-2) with immunoregulatory and cell-differentiating properties. MP-1 stimulates antibody production up to 2.5-fold, while MP-2 reverses tumor-induced T-lymphocyte suppression. These endogenous bone marrow peptides share structural homology with hemoglobin chain fragments, suggesting a conserved signaling role. Bonomarlot is theorized to supplement declining endogenous peptide signaling in aging bone marrow, though direct evidence for this specific product's intracellular activity hasn't been published.
What to Expect
Beginning of the standard 10-day course. Peptides are being absorbed and theoretically reaching bone marrow tissue. No noticeable changes expected during this initial phase. Mild GI adjustment is possible but uncommon.
Completion of standard maintenance course. According to Khavinson bioregulator theory, tissue-specific gene expression modulation is accumulating. Most users won't notice overt changes during a short course. Some report a general sense of improved energy or wellbeing, though this is anecdotal.
Extended therapeutic courses may produce more pronounced effects on bone marrow function. Blood panel changes (CBC, differential) might become detectable in this window, though no published data confirms this for Bonomarlot specifically.
The bioregulator model proposes that gene expression changes persist beyond the active dosing period. Effects are thought to build cumulatively over multiple courses. Repeat bloodwork before the next course to track trends in blood cell counts and immune markers.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bonomarlot (A-20) is a Khavinson-class Cytomax bioregulator derived from bovine bone marrow tissue. It contains short peptides (2-7 amino acids) intended to target bone marrow gene expression. Standard protocol is 2 capsules daily for 10-30 days, repeated every 3-6 months. This is an oral capsule product — no reconstitution or injection is needed. Evidence is limited to the broader Khavinson bioregulator research program; there are no Bonomarlot-specific clinical trials indexed in PubMed.
How to Inject Bonomarlot
Take 1-2 capsules by mouth, 15-20 minutes before a meal, with a small amount of water. The standard protocol is 2 capsules daily for 10 days as a maintenance course, repeated every 6 months. Therapeutic courses may extend to 20-30 days with medical supervision. No reconstitution, injection, or special preparation is needed. Capsules should be swallowed whole — don't chew or open them. Store at room temperature away from moisture and direct sunlight. This product hasn't been evaluated in controlled clinical trials; all dosing is derived from the Khavinson bioregulator program's general recommendations.
Cycling Protocol
Standard Khavinson bioregulator protocol is 10-30 days on, then repeat every 3-6 months. A typical maintenance cycle is 2 capsules daily for 10 days, repeated twice per year. Therapeutic protocols may extend to 30 days. This cycling approach comes from the general Khavinson bioregulator framework — no Bonomarlot-specific cycling studies have been published. Some practitioners combine Bonomarlot with other bioregulators (Thymalin, Crystagen, Vladonix) in staggered cycles targeting different aspects of immune function.
Pharmacokinetics
Source: No published pharmacokinetic data exists for Bonomarlot specifically. The estimated half-life is extrapolated from general short peptide (2-7 amino acid) oral pharmacokinetics. Di- and tripeptides absorbed via PepT1 transporters typically have plasma half-lives of 1-3 hours before proteolytic degradation. This estimate carries very low confidence and should not be used for clinical decision-making.
Loading the interactive decay curve.
Side Effects
No significant adverse effects have been reported in available literature or user reports for Bonomarlot specifically. Mild gastrointestinal discomfort (nausea, bloating) is possible with any oral peptide product. Allergic reactions are theoretically possible since the product is derived from bovine bone marrow tissue. Long-term safety data from controlled studies doesn't exist. Most tolerability information comes from the broader Khavinson bioregulator program rather than Bonomarlot-specific trials.
Contraindications
- Known allergy to bovine-derived products — Bonomarlot is extracted from calf bone marrow tissue
- Active hematologic malignancies (leukemia, lymphoma, myeloma) — stimulating bone marrow activity could be harmful without oncologist guidance
- Pregnancy or breastfeeding — no reproductive safety data exists
- Organ transplant recipients on immunosuppressive therapy — bone marrow stimulation could affect graft tolerance
- Children under 18 — no pediatric dosing or safety data available
- Active bone marrow disorders including myelodysplastic syndromes — medical supervision required
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus) — theoretical risk of counteracting immunosuppression through bone marrow stimulation
- Chemotherapy agents — bone marrow-targeting peptides could interact unpredictably with myelosuppressive drugs; avoid concurrent use
- Other Khavinson bioregulators (Thymalin, Crystagen, Vladonix) — commonly combined in staggered protocols, but no formal interaction studies exist
- Erythropoiesis-stimulating agents (EPO, darbepoetin) — additive bone marrow stimulation is theoretically possible; no data available
- Anticoagulants (warfarin, heparin) — if Bonomarlot affects platelet production, monitoring may be warranted; no documented interactions
- G-CSF or GM-CSF (filgrastim, sargramostim) — concurrent use with bone marrow peptides is unstudied
Storage & Stability
Molecular Profile
Related Peptides
References
- Myelopeptides: bone marrow regulatory mediators (Petrov et al., 1995)PubMed 7647288
- Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity (Petrov et al., 1997)PubMed 9216250
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides (Khavinson et al., 2020)PubMed 32399807
- Peptide bioregulators: the new class of geroprotectors. Results of experimental studies (Khavinson et al., 2012)PubMed 23734519
- Peptide bioregulators: the new class of geroprotectors. Clinical studies results (Khavinson et al., 2013)PubMed 24003726
- Peptide Regulation of Gene Expression: A Systematic Review (Khavinson et al., 2021)Review
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line (Avolio et al., 2022)PubMed 35408963
- Peptide Regulation of Cell Differentiation (Khavinson et al., 2020)PubMed 31808038